Abstract
Objectives: Several pathogens colonize the lungs and cause intermittent or persistent infection in cystic fibrosis (CF). The objective of this study was to assess change in pulmonary pathogen prevalence in clinically relevant subgroups from five years before and until 12 months after elexacaftor/tezacaftor/ivacaftor (ETI) initiation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
